Adamantanyl-histone deacetylase inhibitor H6CAHA exhibits favorable pharmacokinetics and augments prostate cancer radiation sensitivity

International Journal of Radiation Oncology Biology Physics

Volumn 79, Issue 5, 2011, Pages 1541-1548

  Konsoula, Zacharoula ^a   Cao, Hong ^a   Velena, Alfredo ^a   Jung, Mira ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

Histone deacetylase inhibitor; Pharmacodynamics; Pharmacokinetics; Prostate cancer; Radiosensitizer

Indexed keywords

AREA UNDER THE CURVES; CANCER CELLS; CELL LINES; CLINICAL INVESTIGATION; CLONOGENIC ASSAYS; CLONOGENIC SURVIVAL; COMBINATION TREATMENTS; DNA DAMAGES; GROWTH INHIBITION; HISTONE DEACETYLASE INHIBITOR; HUMAN PROSTATE CANCER; HYDROXAMATE; IN-VITRO; IN-VIVO; INTRAPERITONEAL INJECTIONS; LIPOPHILICITY; PHARMACOLOGICAL PROPERTIES; PROSTATE CANCER; PROSTATE CANCER CELLS; PROSTATE CANCERS; RADIATION SENSITIVITY; RADIOSENSITIZERS; THERAPEUTIC VALUES; TUMOR XENOGRAFTS;

CELL CULTURE; CELLS; DNA; GENES; GROWTH (MATERIALS); NUCLEIC ACIDS; PHARMACOKINETICS; RADIATION; RADIOTHERAPY; RATING; REPAIR; SOLUBILITY;

DISEASES;

HISTONE DEACETYLASE INHIBITOR; HISTONE H2AX; N HYDROXY 6 [[(ADAMANTAN 1 YLAMINO)CARBONYL]AMINO]HEXAMIDE; RAD51 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL SURVIVAL; CLONOGENIC ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA REPAIR; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG PENETRATION; DRUG SOLUBILITY; GAMMA IRRADIATION; GENE REPRESSION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RADIOSENSITIVITY; SINGLE DRUG DOSE; TUMOR XENOGRAFT;

ADAMANTANE; ANIMALS; AREA UNDER CURVE; CELL CYCLE PROTEINS; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; DNA DAMAGE; DNA REPAIR; DNA-BINDING PROTEINS; GAMMA RAYS; GENES, BRCA1; GENES, BRCA2; HALF-LIFE; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; HYDROXAMIC ACIDS; MALE; MICE; MICE, NUDE; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; RAD51 RECOMBINASE; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; TUMOR STEM CELL ASSAY; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79952695963     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.11.057     Document Type: Article

References (33)

1. Narlikar GJ, Fan HY, Kingston RE. Cooperation between complexes that regulate chromatin structure and transcription. Cell 2002;108:475-487. (Pubitemid 34260873)
2. Papeleu P, Vanhaecke T, Elaut G, et al. Differential effects of histone deacetylase inhibitors in tumor and normal cells-what is the toxicological relevance? Crit Rev Toxicol 2005;35:363-378.
3. Marks PA, Rifkind RA, Richon VM, et al. Histone deacetylases and cancer:Causes and therapy. Nat Rev Cancer 2001;1:194-202.
4. Rasheed WK, Johnstone RW, Prince HM. Histone deacetylase inhibitors in cancer therapy. Expert Opin Investig Drugs 2007;16:659-678. (Pubitemid 46729100)
5. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009;27:5459-5468.
6. Munshi A, Kurland JF, Nishikawa T, et al. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cancer Res 2005;11:4912-4922. (Pubitemid 41557212)
7. Geng L, Cuneo KC, Fu A, et al. Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. Cancer Res 2006;66:11298-11304. (Pubitemid 46009960)
8. Kelly WK, O'Connor OA, Krug ML, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005;23:3923-3931. (Pubitemid 46218695)
9. Warren KE, McCully C, Dvinge H, et al. Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates. Cancer Chemother Pharmacol 2008;62:433-437. (Pubitemid 351871801)
10. Jung M, Velena A, Chen B, et al. Novel HDAC inhibitors with radiosensitizing properties. Radiat Res 2005;163:488-493. (Pubitemid 41490644)
11. Konsoula Z, Cao H, Velena A, et al. Pharmacokinetics-pharmacodynamics and antitumor activity of mercaptoacetamidebased histone deacetylase inhibitors. Mol Cancer Ther 2009;8:2844-2851.
12. Kozikowski AP, ChenY, Gaysin A, et al. Functional differences in epigenetic modulators-superiority of mercaptoacetamidebased histone deacetylase inhibitors relative to hydroxamates in cortical neuron neuroprotection studies. J Med Chem 2007;50:3054-3061. (Pubitemid 47001248)
13. Zhang Y, Carr T, Dimtchev A, et al. Attenuated DNA damage repair by Trichostatin A through BRCA1 suppression. Radiat Res 2007;168:115-124. (Pubitemid 351292932)
14. Konsoula R, Jung M. In vitro plasma stability, permeability and solubility of mercaptoacetamide histone deacetylase inhibitors. Int J Pharm 2008;361:19-25.
15. Marrocco DL, Tilley WD, Bianco-Miotto T, et al. Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Mol Cancer Ther 2007;6:51-60. (Pubitemid 46209918)
16. Mühlethaler-Mottet A, Flahaut M, Bourloud KB, et al. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro-to anti-apoptotic proteins ratio. BMC Cancer 2006;6:214-227.
17. Hooker JM, Kim SW, Alexoff D, et al. Histone deacetylase inhibitor MS-275 exhibits poor brain penetration: Pharmacokinetic studies of [11C]MS-275 using positron emission tomography. ACS Chem. Neurosci 2010;1:65-73.
18. Lavin MF. Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat Reviews Mol Cell Biol 2008;9:759-769.
19. Celeste A, Fernandez-Capetillo O, Kruhlak MJ, et al. Histone H2AX phosphorylation is dispensable for the initial recognition of DNA breaks. Nat Cell Biol 2003;5:675-679. (Pubitemid 36818091)
20. Pilch DR, Sedelnikova OA, Redon C, et al. Characteristics of g-H2AX foci at DNA double-strand break sites. Biochem Cell Biol 2003;81:123-129. (Pubitemid 37076234)
21. Ryan QC, Headlee D, Acharya M, et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 2005;23:3912-3922. (Pubitemid 46218694)
22. Biade S, Stobbe C, Boyd J, et al. Chemical agents that promote chromatin compaction radiosensitize tumor cells. Int J Radiat Biol 2001;77:1033-1042. (Pubitemid 32977932)
23. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006;6:38-51. (Pubitemid 43054973)
24. Krause WE, Parvez M, Visscher KB, et al. Synthesis and structure of adamantane-containing phosphazenes. Inorg Chem 1996;35:6337-6338. (Pubitemid 126451964)
25. Tominaga K, Haga M. Next generation fine chemicals raw material- adamantane. Chem Econ Eng Rev 1985;17:23-29.
26. Chung YL, Lee MY, Pui NM. Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: Prevention of radiation-induced oral mucositis and inhibition of chemical- induced oral carcinogenesis. Carcinogenesis 2009;30:1387-1397.
27. Insinga A, Monestiroli S, Ronzoni S, et al. Inhibitors of histone deacetylases induce tumor selective apoptosis through activation of the death receptor pathway. Nat Med 2005;11:71-76. (Pubitemid 40215840)
28. Ungerstedt JS, Sowa Y, Xu WS, et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 2005;102:673-678. (Pubitemid 40282724)
29. Kao GD, McKenna WG, Guenther MG, et al. Histone deacetylase 4 interacts with 53BP1 to mediate the DNA damage response. J Cell Biol 2003;160:1017-1027. (Pubitemid 36443871)
30. Chinnaiyan P, Vallabhaneni G, Armstrong E, et al. Modulation of radiation response by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 2005;62:223-229. (Pubitemid 40591946)
31. Camphausen K, BurganW, Cerra M, et al. Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res 2004;64:316-321. (Pubitemid 38114113)
32. Camphausen K, Scott T, Sproull M, et al. Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation. Clin Cancer Res 2004;10:6066-6071. (Pubitemid 39302609)
33. Folkvord S, Ree AH, Furre T, et al. Radiosensitization by SAHA in experimental colorectal carcinoma models- in vivo effects and relevance of histone acetylation status. Int J Radiat Oncol Biol Phys 2009;74:546-552.